KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Invested Capital (2016 - 2025)

NovoCure's Invested Capital history spans 12 years, with the latest figure at $340.5 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 5.47% year-over-year to $340.5 million; the TTM value through Dec 2025 reached $340.5 million, down 5.47%, while the annual FY2025 figure was $340.5 million, 5.47% down from the prior year.
  • Invested Capital for Q4 2025 was $340.5 million at NovoCure, roughly flat from $341.3 million in the prior quarter.
  • Across five years, Invested Capital topped out at $1.0 billion in Q3 2022 and bottomed at $340.5 million in Q4 2025.
  • The 5-year median for Invested Capital is $931.5 million (2021), against an average of $728.5 million.
  • The largest annual shift saw Invested Capital surged 285.09% in 2021 before it crashed 62.48% in 2024.
  • A 5-year view of Invested Capital shows it stood at $972.7 million in 2021, then increased by 3.49% to $1.0 billion in 2022, then dropped by 7.49% to $931.3 million in 2023, then plummeted by 61.33% to $360.2 million in 2024, then dropped by 5.47% to $340.5 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Invested Capital are $340.5 million (Q4 2025), $341.3 million (Q3 2025), and $349.4 million (Q2 2025).